Urothelial Carcinoma
Advertisement
In those who did not undergo EV treatment, NECTIN4 amplifications were not connected with outcomes.
Helen Gao highlights her comparative outcomes analysis of RNU and kidney-sparing surgery in the treatment of high-grade UTUC.
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
The only guideline-recommended endoluminal treatment option for patients with HG UTUC is bacillus Calmette-Guérin.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
Ferring Pharmaceuticals has expanded their Adstiladrin clinical trial program to include 3 new studies in NMIBC.
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
A case study studied the results of 4 patients with locally advanced or oligometastatic UC with complete response on imaging.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
Patients who undergo RNU have comparative or better long-term outcomes than patients undergoing NSS for organ-localized UTUC.
The nomogram is used preoperatively to determine the probability of nodal tropism.
Researchers assessed recurrence rates, overall survival, and disease progression.
Previous trials have revealed that neoadjuvant chemotherapy is an effective treatment path for patients with high-grade UTUC.
Dr. Gupta traces the trajectory of her career and describes her commitment to advancing the field through innovative trials.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.